Renaissance Technologies LLC recently announced the acquisition of new stake in Atreca Inc (NASDAQ:BCEL). The institutional investor has increased its shareholding in the Healthcare company by 8.33% to 0.34 million shares with purchase of 26300.0 shares. This fresh investment now brings its stake to 1.04% valued currently at $45134.0. In addition, Geode Capital Management LLC raised its holdings by 13943.0 to 0.26 million shares.
With over 126.44 million Atreca Inc (BCEL) shares trading Friday and a closing price of $0.36 on the day, the dollar volume was approximately $45.52 million. The shares have shown a negative half year performance of -63.26% and its price on 01/12/24 gained nearly 52.63%. Currently, there are 32.35M common shares owned by the public and among those 29.30M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 10 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 3 of these insider trades were purchases, accounting for 108,750 shares. Insider sales of the common stock occurred on 7 occasions, with total insider shares sold totaling 337,615 shares.
The top 3 mutual fund holders in Atreca Inc are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Bridgeway Ultra Small Company Mar. Vanguard Total Stock Market ETF owns 0.91 million shares of the company’s stock, all valued at over $0.12 million. Bridgeway Ultra Small Company Mar now owns shares totaling to 0.46% of the shares outstanding.
Shares of Atreca Inc (NASDAQ: BCEL) opened at $0.26, up $0.03 from a prior closing price of $0.23. However, the script later moved the day high at 0.4445, up 52.63%. The company’s stock has a 5-day price change of 208.30% and -6.24% over the past three months. BCEL shares are trading 170.00% year to date (YTD), with the 12-month market performance down to -75.08% lower. It has a 12-month low price of $0.10 and touched a high of $2.05 over the same period. BCEL has an average intraday trading volume of 6.26 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 100.50%, 70.02%, and -42.64% respectively.
Institutional ownership of Atreca Inc (NASDAQ: BCEL) shares accounts for 22.43% of the company’s 32.35M shares outstanding. Mutual fund holders own 21.47%, while other institutional holders and individual stakeholders account for 5.54% and 14.65% respectively.
It has a market capitalization of $14.12M and a beta (3y monthly) value of 1.12. The earnings-per-share (ttm) stands at -$2.49. Price movements for the stock have been influenced by the stock’s volatility, which stands at 36.60% over the week and 20.85% over the month.
Analysts forecast that Atreca Inc (BCEL) will achieve an EPS of -$0.39 for the current quarter, -$0.22 for the next quarter and -$0.72 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.48 while analysts give the company a high EPS estimate of -$0.22. Comparatively, EPS for the current quarter was -$0.53 a year ago. Earnings per share for the fiscal year are expected to increase by 19.05%, and 57.84% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Atreca Inc (BCEL) as a “Strong Buy” at a consensus score of 1.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the BCEL, a number of firms have released research notes about the stock. Robert W. Baird stated their Outperform rating for the stock in a research note on June 04, 2021, with the firm’s price target at $30-$27.
